Sitryx completes enrollment early in Phase 1b oral PKM2 drug for eczema
SYX-5219 finished enrolling ahead of schedule and now heads to a Q4 2026 readout that will test whether early biomarker signals translate into clinical effect.
Executive Summary
- Sitryx Therapeutics finished enrolling its Phase 1b trial of an oral PKM2 modulator in atopic dermatitis patients ahead of schedule, moving the program to its next data readout without any operational delay.
- The trial's primary measure is safety, but its earlier-stage data already showed the drug engaging its target and moving an inflammation biomarker, so the coming readout is the first chance to see whether that translates into a clinical response in patients rather than healthy volunteers.
- The atopic dermatitis field is dense with approved biologics and oral therapies targeting different mechanisms entirely, while no other clinical-stage program targets the same enzyme in this disease, leaving the asset's mechanism clinically untested rather than crowded out.
- A readout that shows a dose-dependent effect on disease severity alongside a clean safety profile would be the first clinical evidence that modulating this metabolic target can move an inflammatory skin disease, not just a biomarker.
The milestone
Sitryx Therapeutics announced on June 22, 2026 that it completed enrollment in the Phase 1b portion of NCT07558668, a randomized, double-blind, placebo-controlled trial evaluating SYX-5219 in adults with moderate to severe atopic dermatitis. The company said enrollment finished ahead of schedule, which it attributed to investigator and patient interest in an oral option for a condition typically treated with topical agents, injectable biologics, or oral JAK inhibitors. Chief Executive Officer Iain Kilty said the trial reflects "the strength of our execution and the opportunity we see with SYX-5219 to deliver lasting patient benefit". The registry lists the study as still Recruiting with a target enrollment of 149 across Part 1, Part 2, and Part 3, spanning healthy volunteers and atopic dermatitis patients at sites in the United States, Germany, the United Kingdom, Bulgaria, Denmark, and Ireland. Sitryx+1Sitryx Completes Enrollment in Phase 1b Trial of First-in-Class Oral PKM2 Modulator SYX-5219 in ...Jun 22, 2026A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic DermatitisNCT07558668
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial tests
The registered primary endpoint is the proportion of participants with treatment-emergent adverse events, a safety measure, not a clinical efficacy endpoint. Secondary endpoints track plasma and urine concentrations of SYX-5219, standard pharmacokinetic measures for an early-phase study. The trial carries a primary completion date of August 30, 2026 and an overall completion date of September 30, 2026, both ahead of the disclosed Q4 2026 data window Sitryx cited in its enrollment announcement. The design is not registrational, so this readout will inform whether the program advances to larger, efficacy-powered studies rather than support a regulatory filing on its own. NCT07558668+1A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic DermatitisNCT07558668Sitryx Completes Enrollment in Phase 1b Trial of First-in-Class Oral PKM2 Modulator SYX-5219 in ...Jun 22, 2026
The mechanistic anchor
The Q4 2026 readout builds on Phase 1a data presented at the Society for Investigative Dermatology's May 2026 meeting, where SYX-5219 was reported safe and well tolerated across doses in 96 healthy adults, with pyruvate kinase M2 target engagement above the 95% effective-concentration threshold and reductions in serum CCL17/TARC, a biomarker of type 2 inflammation, at doses of 30 mg and above. That gives the Phase 1b readout a specific bar beyond safety: whether the same biomarker movement and tolerability profile hold in atopic dermatitis patients, where the trial also collects an efficacy signal even though it is not the prespecified primary measure. SitryxSitryx Completes Enrollment in Phase 1b Trial of First-in-Class Oral PKM2 Modulator SYX-5219 in ...Jun 22, 2026
Competitive landscape
No other industry-sponsored clinical trial identified in the same target class, pyruvate kinase M2, is testing an atopic dermatitis indication; the sole comparable PKM2-directed program in clinical testing, ProAgio, is being developed for pancreatic cancer. Within atopic dermatitis itself, the active competitive field is built on IL-4Rα, JAK1, and OX40L mechanisms, including Dupilumab, Upadacitinib, and Amlitelimab, none of which share SYX-5219's metabolic-enzyme mechanism. That leaves SYX-5219's mechanism without a validated clinical precedent in this disease: the Phase 1b readout is the first data point testing whether PKM2 modulation moves disease activity in patients, not just a biomarker in healthy volunteers.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.